Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease
Summary
This summary is machine-generated.The epsilon4 allele of apolipoprotein E (apo E) increases Alzheimer's disease risk. Human apo E3 and apo E4 isoforms suppressed amyloid-beta deposition in transgenic mice, suggesting a protective role against Alzheimer's pathology.
Area Of Science
- Neuroscience
- Genetics
- Biochemistry
Background
- The epsilon4 allele of apolipoprotein E (apo E) is a significant risk factor for Alzheimer's disease (AD).
- Interactions between apo E and amyloid-beta (Abeta) are hypothesized to contribute to AD pathogenesis.
- Understanding the differential effects of human apo E isoforms on Abeta is crucial for AD research.
Purpose Of The Study
- To investigate the in vivo effects of human apo E3 and apo E4 isoforms on Abeta deposition.
- To compare the influence of human apo E on Abeta pathology with mouse apo E and a complete absence of apo E.
Main Methods
- Transgenic mice expressing a mutant amyloid precursor protein (APPV717F) were bred with mice expressing human apo E3 or apo E4 on a mouse apo E null background.
- Abeta deposition was assessed in the brains of these mice at nine months of age.
- Comparisons were made between mice with human apo E, mouse apo E, and no apo E.
Main Results
- APPV717F transgenic mice lacking mouse apo E showed Abeta deposition by nine months.
- Both human apo E3 and apo E4 isoforms markedly suppressed early Abeta deposition compared to mice lacking apo E.
- Human apo E isoforms demonstrated a greater suppression of Abeta deposition than mouse apo E.
Conclusions
- Human apo E isoforms (E3 and E4) significantly decrease Abeta deposition in vivo.
- These findings suggest that human apo E isoforms may enhance Abeta clearance or reduce aggregation.
- The results highlight a potential mechanism linking apo E to Alzheimer's disease risk and progression.
View abstract on PubMed